Retatrutide Price Index by Supplier: Reading the Spread

A retatrutide price index by supplier is a normalized comparison of what different sellers charge, expressed relative to a common baseline rather than as raw dollar figures. Instead of asking “what does Supplier A charge,” an index asks “how does Supplier A’s price compare to the market average,” which is a more useful question when vial sizes, bundle structures, and listing formats differ from one seller to the next. The index itself is not published anywhere authoritative — it is something a buyer or tracker constructs from public listings, and the construction method matters as much as the underlying numbers.

Why Raw Prices Don’t Compare Cleanly

Two suppliers rarely list retatrutide the same way. One might price a 5 mg vial, another a 10 mg vial, and a third might bundle three vials under a single line-item price. Comparing the sticker prices directly answers a question nobody is actually asking. What matters is the price per milligram, calculated the same way for every supplier before any comparison happens.

This is the first step in building any supplier index: convert every listing to price per mg before doing anything else. A vial’s total price divided by its labeled mg content gives a number that is finally comparable across sellers, regardless of how each one chose to package the product.

Building the Index: A Worked Example

Once every supplier’s price is expressed per mg, the index step is a simple normalization: divide each supplier’s per-mg price by the group average, then multiply by 100. A supplier priced exactly at the market average lands at 100. A supplier priced above average lands above 100, and a supplier priced below average lands below 100.

Suppose four suppliers’ retatrutide listings normalize to the following per-mg prices:

Supplier	Price per mg	Index value
Supplier A	$16.00	91.43
Supplier B	$19.00	108.57
Supplier C	$14.00	80.00
Supplier D	$21.00	120.00

The group average is (16 + 19 + 14 + 21) ÷ 4 = $17.50 per mg. Each supplier’s index value is its price divided by that average, times 100: Supplier A is 16 ÷ 17.5 × 100 = 91.43, Supplier B is 19 ÷ 17.5 × 100 = 108.57, Supplier C is 14 ÷ 17.5 × 100 = 80.00, and Supplier D is 21 ÷ 17.5 × 100 = 120.00. The four index values sum to exactly 400, which is what four suppliers averaging to 100 should produce, and is a useful check that the math was done correctly.

Read this way, Supplier C is priced 20 percent below the group’s average per-mg cost, and Supplier D is priced 20 percent above it. Neither of those relationships is visible from the raw dollar figures alone — a reader has to normalize first to see it.

What the Index Does and Does Not Tell You

An index value describes relative position, not absolute value. A supplier sitting at 120 is expensive only relative to the other suppliers included in that particular index — if the whole group happens to be priced high compared to the broader retatrutide market, an index built only from that group will not reveal it. The index is a snapshot of the sample it was built from, and the sample matters as much as the arithmetic.

It also says nothing about why a supplier sits where it does. A high index value can reflect a higher-quality listing with third-party testing documentation, a smaller batch size with higher per-unit overhead, or simply a markup with no accompanying difference in what is being sold. The index flags where to look closer; it does not replace looking closer.

Variables That Shift Supplier Index Values

A handful of factors consistently explain why one supplier’s index value differs from another’s, independent of the underlying compound itself:

• Vial size mix. A supplier whose catalog skews toward larger vials will often show a lower average per-mg price, since larger vials commonly carry a lower marginal cost per mg.
• Shipping treatment. Some suppliers fold shipping into the listed price; others charge it separately. An index that mixes both without adjusting for this will misstate the comparison.
• Testing and documentation claims. Listings referencing third-party purity testing tend to sit at a different price point than listings without it, which shows up as index movement unrelated to the compound itself.
• Snapshot timing. Supplier pricing changes over time, so an index built from listings pulled on different dates is comparing a moving target, not a fixed one.

None of these are visible in the index number itself — they only surface when the listings behind the number are read closely.

Using an Index Without Overreading It

The most common mistake in reading a supplier price index is treating index position as a quality signal. It is a price signal only. A supplier at 80 is cheaper per mg than the group average; it says nothing about testing rigor, batch consistency, or listing accuracy. Retacost’s own tracking of retatrutide pricing exists to make the per-mg and index-level comparisons easier to construct, while a broader reference on adjacent GLP-1 research compounds, such as peer retatrutide listing catalogs, is useful for checking whether a given supplier’s pricing pattern for retatrutide also shows up across the rest of that supplier’s catalog or is specific to this one compound.

Before trusting any index value, confirm three things about the listings behind it: that the mg figure is the labeled vial content rather than a bundle total, that shipping is treated consistently across every supplier in the sample, and that all listings were pulled close enough in time to represent the same market moment. A single outlier supplier with an unusually large or small vial size can also pull a small-sample average in a way that a larger sample would smooth out, so index values built from very few suppliers should be read as directional rather than precise. For the underlying listing itself, heezresearch.com’s retatrutide page states the vial size and price that would serve as one data point in a supplier index like the one above.

Summary

A retatrutide price index by supplier normalizes per-mg prices to a common baseline so that suppliers with different vial sizes and listing formats become comparable. Building one correctly means converting every listing to price per mg first, dividing each by the group average, and treating the resulting index values as relative price position rather than a judgment on quality. Vial size mix, shipping treatment, documentation claims, and snapshot timing all move index values independently of the compound itself, which is why the same set of suppliers can produce different-looking indexes depending on how and when the underlying listings were read.